The conversion from accelerated approval to regular approval was based on data from the KEYNOTE-158 trial, the KEYNOTE-164 trial, and the KEYNOTE-051 trial.
More than 20% of US patients diagnosed with cancer during pregnancy may be unable to terminate that pregnancy due to abortion laws in their state, a new study suggests.
Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.
Researchers are conducting a phase 3 trial to compare sotorasib plus panitumumab with investigator’s choice of therapy in patients with previously treated, KRAS p.G12C-mutated metastatic colorectal cancer.
Researchers are conducting a phase 3 trial to compare standard care with combination tucatinib, trastuzumab, and chemotherapy as first-line treatment in HER2-positive, unresectable or metastatic colorectal cancer.
Researchers are comparing nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice of chemotherapy in MSI-H/dMMR, recurrent or metastatic colorectal cancer.
The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.
Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival if they enroll on a clinical trial than if they receive standard care.
Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.
Ribociclib plus letrozole elicits responses in patients with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum, a phase 2 study suggests.
The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Mammography use is still higher among White patients than among American Indian patients, but the gap is narrowing due to declining mammography use in White patients.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Adding vistusertib to treatment with paclitaxel does not improve outcomes in patients with platinum-resistant or -refractory ovarian cancer, a phase 2 trial suggests.
Postoperative adverse events can delay chemotherapy but do not affect survival outcomes in patients with platinum-sensitive, recurrent ovarian cancer, a study suggests.
The FDA approved the combination to treat pediatric patients 1 year of age and older who have low-grade glioma with a BRAF V600E mutation and require systemic therapy.
A majority of physicians surveyed said that prior authorization results in increased use of health care resources, and one-third said prior authorization led to a serious adverse event for a patient.
Among older patients with diabetes, metformin was associated with a reduced risk of cancer, but the combination of aspirin and metformin was associated with an increased risk of cancer death.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
New research suggests that men with localized prostate cancer have low prostate cancer-specific mortality at 15 years, regardless of the treatment they receive.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.